TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Timothy P. Hughes, Devendra Hiwase et al.|Blood|2014Cited by 102
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemiaNaranie Shanmuganathan, Timothy P. Hughes, Ilaria S. Pagani et al.|Blood|2020Cited by 86
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapyEva Nievergall, Deborah L. White, John Reynolds et al.|Leukemia|2016Cited by 50
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohortMithun Vinod Shah, Devendra Hiwase, Kevin Hung et al.|Blood Cancer Journal|2025Cited by 6